Palvella Therapeutics, Inc. (PVLA)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.71B
- P/E ratio
- —
- EPS
- —
- Volume
- 558,087
- 52-week high
- —
- 52-week low
- —
- Open
- $155.72
- Day high
- $157.55
- Day low
- $123.97
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$41.72M | -$3.71 |
| 2024 | — | -$17.43M | -$7.83 |
| 2023 | $42.81M | $18.69M | $2.17 |
| 2022 | $25.9M | -$33.28M | -$0.45 |
| 2021 | $31.42M | -$45.74M | -$0.71 |
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
- CEO
- Wesley H. Kaupinen
- Employees
- 29
- Country
- US
- IPO date
- Jan 2, 2015
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Palvella Therapeutics, Inc.'s stock price today?
- PVLA is trading at $124.15 as of Jul 20, 2026.
- What is Palvella Therapeutics, Inc.'s market cap?
- Palvella Therapeutics, Inc. (PVLA) has a market capitalization of $1.71B.
- Does Palvella Therapeutics, Inc. pay a dividend?
- Palvella Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Palvella Therapeutics, Inc. in?
- Palvella Therapeutics, Inc. operates in the Healthcare sector.